To Go or Not to Go?-Targeting Tregs Traveling in Tumors.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
16
04
2021
accepted:
20
04
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
9
10
2021
Statut:
ppublish
Résumé
Regulatory T cells (Treg) are one of the major impediments to effective antitumor immunity and successful immunotherapy. Elevated intratumoral Treg frequencies, observed in a variety of malignancies, have been associated with poor prognosis. In this issue of
Identifiants
pubmed: 34087782
pii: 81/11/2817
doi: 10.1158/0008-5472.CAN-21-1203
doi:
Substances chimiques
Gpr15 protein, mouse
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2817-2819Commentaires et corrections
Type : CommentOn
Type : CommentOn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;34:690.
Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, et al. The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy. Adv Cancer Res. 2015;128:1–68.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2020;1:1153–66.
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019;25:759–66.
Campbell JR, McDonald1 BR, Mesko PM, Siemers NO, Singh PB, Selby M, et al. Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models. Cancer Res. 2021;81:2983–94.
Adamczyk A, Pastille E, Kehrmann J, Vu VP, Geffers R, Wasmer MH, et al. GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer. Cancer Res. 2021;81:2970–82.
Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, et al. Phase Ia study of FoxP3+ CD4 treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21:4327–36.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116:9999–10008.
Kim SV, Xiang WV, Kwak C, Yang Y, Lin XW, Ota M, et al. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science. 2013;340:1456–9.
Bilsborough J, Viney JL. GPR15: a tale of two species. Nat Immunol. 2015;16:137–9.